Boston Therapeutics' sugardown in clinical trials reduces glucose, fructose and insulin
sugardown reduces total glycemic index including fructose by up to 28% and insulin by up to 18%.
Boston Therapeutics has released final trial results from its proof of concept (POC) Sydney University study that showed consumption of sugardown tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose and insulin responses to the sugary soft drink beverage. Every subject had a favourable response. Specifically, two sugardown tablets were found to reduce glucose levels (and by association fructose exposure) by up to 20 percent and the insulin response by up to 14%. Four sugardown tablets were found to reduce total glucose levels by up to 28% and insulin response by up to 18%. The study results indicate an average reduction in glycemic index (GI) an important measure of healthy nutritional management of approximately 10% following soft drink consumption with two sugardown tablets.
David Platt, CEO of Boston Therapeutics, said: "The clinical study results provide confirming support that sugardown can be effective in reducing glucose, (fructose by implication) and insulin response when consumed with sugary beverages. Sucrose and HFC, high fructose corn syrup, are a combination of glucose and fructose and preventing the breakdown is an important healthy diet management tool. The consumption of sugary soft drink beverages can lead to a wide range of health problems that through GI management can delay or reduce ill effects and poor health, including obesity, type 2 diabetes, fatty liver disease, high blood pressure, and even brain and cognitive disorders. All of which have been implicated in animal models. We will add the clinical data on sugardown's effects on sugary beverages as a section in our regulatory submissions. We believe these additional clinical data continue to be supportive of sugardown benefits as a dietary supplement classification. These clinical data will aid people with managing and reducing their overall systemic exposure to sugar after every meal."
sugardown in its present formulation is a natural sugar blocker dietary supplement product made entirely from an non-digestible sugar molecule that can help people maintain healthier weight levels and is the first chewable tablet of its kind. In a previous study, sugardown demonstrated significant reduction of glucose and insulin Area Under the Curve when taken with rice, a food with a 100% GI. Sugary soft drinks that also have high glycemic index, include sucrose and maltose which is also found in beer.
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance